ArticleBMC gastroenterology2025
Concurrent nonalcoholic fatty liver disease may decrease liver fibrosis severity in patients with primary biliary cholangitis.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dual cut-offs and beyond: Expanding the role of transient elastography in primary biliary cholangitis.World journal of gastroenterology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to evaluate how nonalcoholic fatty liver disease (NAFLD) impacts the progression and prognosis of primary biliary cholangitis (PBC).
methodsThis retrospective study enrolled patients diagnosed with PBC. NAFLD patients were identified according to the 2023 American Association for the Study of Liver Diseases guidelines. The primary outcome measured the percentage of patients achieving a complete biochemical response as defined by the Paris criteria, while secondary outcomes included non-invasive fibrosis scoring systems and a transplantation-free survival risk model. Statistical analyses employed independent samples Student's t-test or Mann-Whitney U test for continuous variables and Pearson's chi-square or Fisher's exact test for categorical variables, with significance set at a two-tailed P-value of less than 0.05.
resultsAmong 363 patients diagnosed with PBC, 87 (24.0%) were also diagnosed with NAFLD. Biochemical response rates did not differ significantly between patients with only PBC and those with concurrent PBC and NAFLD (P>0.05). However, after one year of ursodesoxycholic acid (UDCA) treatment, significant differences were observed in aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis 4 (FIB-4) score between PBC patients with and without NAFLD (APRI: 0.35 vs. 0.47, P = 0.02; FIB-4 score: 1.95 vs. 2.53, P = 0.01). The GLOBE score revealed that patients with both PBC and NAFLD had higher 5-, 10-, and 15-year liver transplant-free survival rates compared to those with only PBC (81.9%, 58.3%, and 38.0% respectively, all P < 0.05).
conclusionsPatients with concurrent PBC and NAFLD do not significantly impact the biochemical response to UDCA but may improve the degree of liver fibrosis and long-term prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.